SG/CALL/NOVO-NORDISK B/1180/0.1/20.09.24 | Market Closed - Boerse Frankfurt Warrants 01:20:59 08/06/2024 am IST | ||
| 0.15 EUR | +15.38% |
|
| Current month | +188.46% | ||
| 1 month | +145.90% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 07/24/07 | 0.15 | +15.38% |
| 06/24/06 | 0.13 | +39.78% |
| 05/24/05 | 0.093 | +27.40% |
| 04/24/04 | 0.073 | +46.00% |
| 03/24/03 | 0.05 | -3.85% |
Real-time Boerse Frankfurt Warrants
Last update June 08, 2024 at 01:20 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SW7HUU |
| ISIN | DE000SW7HUU7 |
| Date issued | 11/03/2024 |
| Strike | 1,180 kr |
| Maturity | 20/09/2024 (104 Days) |
| Parity | 10 : 1 |
| Emission price | 0.41 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.44 € |
|---|---|
| Lowest since issue | 0.038 € |
| Spread | 0.01 € |
| Spread % | 6.25% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
984
DKK
Average target price
920.8
DKK
Spread / Average Target
-6.43%
- Stock Market
- Warrants
- Warrant
